What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing?

What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing?

What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing? “Broad molecular profiling” is already recommended for 1st line metastatic NSCLC. Do you think this is a trend that will come to other tumor types?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Suzhan Zhang, MD

Professor Suzhan Zhang, MD

Director, Cancer Institute
Zhejiang University Multidisciplinary Diagnosis and Treatment Center for Colorectal Cancer
Zhejiang University School of Medicine
Hangzhou, China